Luzindole
Based on 18 publication(s) in Google Scholar
Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel1b) over MT1 (Mel1a) with Ki values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.53%
- CAS No.: 117946-91-5
- 화학식: C19H20N2O
- 분자량:292.37
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Luzindole
More- Redox Biol. 2025 Dec:88:103939. [Abstract]
- Cell Mol Biol Lett. 2024 Feb 2;29(1):22. [Abstract]
- Free Radic Biol Med. 2022 Aug 1:188:337-350. [Abstract]
- Stem Cell Res Ther. 2021 Apr 29;12(1):254. [Abstract]
- J Pineal Res. 2026 Mar;78(2):e70139. [Abstract]
- Cell Mol Life Sci. 2022 Nov 30;79(12):610. [Abstract]
- Int J Mol Sci. 2023 May 14;24(10):8740. [Abstract]
- Zool Res. 2022 Jul 18;43(4):537-551. [Abstract]
- Int Immunopharmacol. 2022 Aug:109:108778. [Abstract]
- Food Sci Nutr. 2026 Jan 27;14(1):e71465. [Abstract]
- Pest Manag Sci. 2021 Jul;77(7):3561-3570. [Abstract]
- Eur Cell Mater. 2025 Feb 20;49:55-70.
- Adv Biol (Weinh). 2024 Jan;8(1):e2300424. [Abstract]
- Tissue Cell. 2025 Sep 6:98:103131. [Abstract]
- J Mammal. 2024 May 15.
- SSRN. 2025 Jun 6.
- Research Square Preprint. 2022 Jan.
- Research Square Preprint. 2020 Dec.
Biological Activity
|
MT2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Melanophore | IC50 |
2.1 μM
Compound: luzindole
|
Inhibitory concentration against melatonin-induced pigment aggregation by 50% in Xenopus laevis dermal melanophore cell line
Inhibitory concentration against melatonin-induced pigment aggregation by 50% in Xenopus laevis dermal melanophore cell line
|
[PMID: 9484496] |
Luzindole (N-0774) (5-10 μg/ml) inhibits antigen-specific proliferation of the MBP-reactive LV-4 T cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
? Luzindole (N-0774) (30 mg/kg i.p.) reduces the time of immobility in a dose-dependent manner, the effect being more pronounced at midnight (60% reduction) than at noon (39% reduction). The effect of luzindole is time-dependent, showing a maximal effect at 60 min. The anti-immobility effect of luzindole (10 mg/kg i.p.) is prevented by the administration of melatonin (30 mg/kg i.p.). Luzindole (30 mg/kg i.p.) did not modify the time of immobility either at noon or midnight in the albino ND/4 mouse, or in the C57BL/6J mouse, which does not produce melatonin[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Twenty-three- to 12-week-old(SJL X PL/J ) F1 mice[2]
-
Dosage:30 mg/kg
-
Administration:i.p.; days 0-5 (between 23: 00 and 1: 00 under conditions of minimal lighting)
-
Result:Effectively prevented experimental autoimmune encephalomyelitis.
Chemical Information
-
CAS No. 117946-91-5
-
Appearance Solid
-
분자량 292.37
-
화학식 C19H20N2O
-
Color Off-white to light yellow
-
SMILES
CC(NCCC1=C(CC2=CC=CC=C2)NC3=C1C=CC=C3)=O
-
Synonyms
N-0774
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Melatonin attenuates atherosclerotic plaque vulnerability through SIRT6-dependent regulation of vascular smooth muscle cells senescence. [Abstract]2025 Dec:88:103939. PMID: 41308252 -
Cell Mol Biol Lett
IP3R1-mediated MAMs formation contributes to mechanical trauma-induced hepatic injury and the protective effect of melatonin. [Abstract]2024 Feb 2;29(1):22. PMID: 38308199 -
Free Radic Biol Med
Canonical Wnt signaling works downstream of iron overload to prevent ferroptosis from damaging osteoblast differentiation. [Abstract]2022 Aug 1:188:337-350. PMID: 35752374 -
Stem Cell Res Ther
Melatonin induces the rejuvenation of long-term ex vivo expanded periodontal ligament stem cells by modulating the autophagic process. [Abstract]2021 Apr 29;12(1):254. PMID: 33926537 -
J Pineal Res
Melatonin Promotes the Synthesis and Secretion of Growth Hormone in the Adenohypophysis by Activating the cAMP/FOXO1 Pathway. [Abstract]2026 Mar;78(2):e70139. PMID: 41870323 -
Cell Mol Life Sci
A novel mechanism for the protection against acute lung injury by melatonin: mitochondrial quality control of lung epithelial cells is preserved through SIRT3-dependent deacetylation of SOD2. [Abstract]2022 Nov 30;79(12):610. PMID: 36449070 -
Int J Mol Sci
Preparation of Melatonin-Loaded Nanoparticles with Targeting and Sustained Release Function and Their Application in Osteoarthritis. [Abstract]2023 May 14;24(10):8740. PMID: 37240086 -
Zool Res
Production of functional sperm from in vitro-cultured premeiotic spermatogonia in a marine fish. [Abstract]2022 Jul 18;43(4):537-551. PMID: 35616259 -
Int Immunopharmacol
Melatonin relieves Th17/CD4-CD8- T cells inflammatory responses via nuclear-receptor dependent manner in peripheral blood of primary Sjögren's syndrome. [Abstract]2022 Aug:109:108778. PMID: 35537347 -
Food Sci Nutr
Nutritional Modulation of Melatonin-SIRT1 Signaling by Octanoic Acid-Rich Enteral Nutrition Protects Against Radiation-Induced Intestinal Injury. [Abstract]2026 Jan 27;14(1):e71465. PMID: 41607646 -
Pest Manag Sci
MicroRNA-315-5p promotes rice black-streaked dwarf virus infection by targeting a melatonin receptor in the small brown planthopper. [Abstract]2021 Jul;77(7):3561-3570. PMID: 33840148 -
-
Adv Biol (Weinh)
Melatonin Exerts an Anti-Panoptoic Role in Spinal Cord Ischemia-Reperfusion Injured Rats. [Abstract]2024 Jan;8(1):e2300424. PMID: 37786299 -
Tissue Cell
Melatonin alleviates cholestatic liver injury through modulating gut microbiota and activating the NRF2/HO-1 antioxidant pathway. [Abstract]2025 Sep 6:98:103131. PMID: 40925262 -
-
-
-
용액&용해도
DMSO : 100 mg/mL (342.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dubocovich ML, et al. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75. [Content Brief]
[2]. Constantinescu CS, et al. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology. 1997;65(4):190-4. [Content Brief]
[3]. Dubocovich ML Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavioral despair test. Eur J Pharmacol. 1990 Jul 3;182(2):313-25. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4203 mL | 17.1016 mL | 34.2032 mL | 85.5081 mL |
| 5 mM | 0.6841 mL | 3.4203 mL | 6.8406 mL | 17.1016 mL | |
| 10 mM | 0.3420 mL | 1.7102 mL | 3.4203 mL | 8.5508 mL | |
| 15 mM | 0.2280 mL | 1.1401 mL | 2.2802 mL | 5.7005 mL | |
| 20 mM | 0.1710 mL | 0.8551 mL | 1.7102 mL | 4.2754 mL | |
| 25 mM | 0.1368 mL | 0.6841 mL | 1.3681 mL | 3.4203 mL | |
| 30 mM | 0.1140 mL | 0.5701 mL | 1.1401 mL | 2.8503 mL | |
| 40 mM | 0.0855 mL | 0.4275 mL | 0.8551 mL | 2.1377 mL | |
| 50 mM | 0.0684 mL | 0.3420 mL | 0.6841 mL | 1.7102 mL | |
| 60 mM | 0.0570 mL | 0.2850 mL | 0.5701 mL | 1.4251 mL | |
| 80 mM | 0.0428 mL | 0.2138 mL | 0.4275 mL | 1.0689 mL | |
| 100 mM | 0.0342 mL | 0.1710 mL | 0.3420 mL | 0.8551 mL |